Skip to main content
Figure 1 | Journal of Immune Based Therapies and Vaccines

Figure 1

From: Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

Figure 1

Kinetic of Anti EGF antibodies and serum EGF concentrations in the Phase III Trial (Vaccination with high dose/4 anatomic sites). The anti-EGF antibody titer was inversely correlated to the EGF serum concentration (spearman r correlation, p < 0.05). in this high dose/multiple sites study the decay below the 500 pg/mL threshold had effect after 76 days of vaccination.

Back to article page
\